103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED: 720 ILCS 570/204 from Ch. 56 1/2, par. 1204720 ILCS 570/206 from Ch. 56 1/2, par. 1206 Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances. LRB103 35349 RLC 65413 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED: 720 ILCS 570/204 from Ch. 56 1/2, par. 1204720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances. LRB103 35349 RLC 65413 b LRB103 35349 RLC 65413 b A BILL FOR
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED:
720 ILCS 570/204 from Ch. 56 1/2, par. 1204720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/206 from Ch. 56 1/2, par. 1206
Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances.
LRB103 35349 RLC 65413 b LRB103 35349 RLC 65413 b
LRB103 35349 RLC 65413 b
A BILL FOR
HB4352LRB103 35349 RLC 65413 b HB4352 LRB103 35349 RLC 65413 b
HB4352 LRB103 35349 RLC 65413 b
1 AN ACT concerning criminal law.
2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 204 and 206 as follows:
6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
7 (Text of Section before amendment by P.A. 103-245)
8 Sec. 204. (a) The controlled substances listed in this
9 Section are included in Schedule I.
10 (b) Unless specifically excepted or unless listed in
11 another schedule, any of the following opiates, including
12 their isomers, esters, ethers, salts, and salts of isomers,
13 esters, and ethers, whenever the existence of such isomers,
14 esters, ethers and salts is possible within the specific
15 chemical designation:
16 (1) Acetylmethadol;
17 (1.1) Acetyl-alpha-methylfentanyl
18 (N-[1-(1-methyl-2-phenethyl)-
19 4-piperidinyl]-N-phenylacetamide);
20 (2) Allylprodine;
21 (3) Alphacetylmethadol, except
22 levo-alphacetylmethadol (also known as levo-alpha-
23 acetylmethadol, levomethadyl acetate, or LAAM);
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED:
720 ILCS 570/204 from Ch. 56 1/2, par. 1204720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/206 from Ch. 56 1/2, par. 1206
Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances.
LRB103 35349 RLC 65413 b LRB103 35349 RLC 65413 b
LRB103 35349 RLC 65413 b
A BILL FOR
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/206 from Ch. 56 1/2, par. 1206
LRB103 35349 RLC 65413 b
HB4352 LRB103 35349 RLC 65413 b
HB4352- 2 -LRB103 35349 RLC 65413 b HB4352 - 2 - LRB103 35349 RLC 65413 b
HB4352 - 2 - LRB103 35349 RLC 65413 b
1 (4) Alphameprodine;
2 (5) Alphamethadol;
3 (6) Alpha-methylfentanyl
4 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
5 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
6 propanilido) piperidine;
7 (6.1) Alpha-methylthiofentanyl
8 (N-[1-methyl-2-(2-thienyl)ethyl-
9 4-piperidinyl]-N-phenylpropanamide);
10 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
11 (7.1) PEPAP
12 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
13 (8) Benzethidine;
14 (9) Betacetylmethadol;
15 (9.1) Beta-hydroxyfentanyl
16 (N-[1-(2-hydroxy-2-phenethyl)-
17 4-piperidinyl]-N-phenylpropanamide);
18 (10) Betameprodine;
19 (11) Betamethadol;
20 (12) Betaprodine;
21 (13) Clonitazene;
22 (14) Dextromoramide;
23 (15) Diampromide;
24 (16) Diethylthiambutene;
25 (17) Difenoxin;
26 (18) Dimenoxadol;
HB4352 - 2 - LRB103 35349 RLC 65413 b
HB4352- 3 -LRB103 35349 RLC 65413 b HB4352 - 3 - LRB103 35349 RLC 65413 b
HB4352 - 3 - LRB103 35349 RLC 65413 b
1 (19) Dimepheptanol;
2 (20) Dimethylthiambutene;
3 (21) Dioxaphetylbutyrate;
4 (22) Dipipanone;
5 (23) Ethylmethylthiambutene;
6 (24) Etonitazene;
7 (25) Etoxeridine;
8 (26) Furethidine;
9 (27) Hydroxpethidine;
10 (28) Ketobemidone;
11 (29) Levomoramide;
12 (30) Levophenacylmorphan;
13 (31) 3-Methylfentanyl
14 (N-[3-methyl-1-(2-phenylethyl)-
15 4-piperidyl]-N-phenylpropanamide);
16 (31.1) 3-Methylthiofentanyl
17 (N-[(3-methyl-1-(2-thienyl)ethyl-
18 4-piperidinyl]-N-phenylpropanamide);
19 (32) Morpheridine;
20 (33) Noracymethadol;
21 (34) Norlevorphanol;
22 (35) Normethadone;
23 (36) Norpipanone;
24 (36.1) Para-fluorofentanyl
25 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
26 4-piperidinyl]propanamide);
HB4352 - 3 - LRB103 35349 RLC 65413 b
HB4352- 4 -LRB103 35349 RLC 65413 b HB4352 - 4 - LRB103 35349 RLC 65413 b
HB4352 - 4 - LRB103 35349 RLC 65413 b
1 (37) Phenadoxone;
2 (38) Phenampromide;
3 (39) Phenomorphan;
4 (40) Phenoperidine;
5 (41) Piritramide;
6 (42) Proheptazine;
7 (43) Properidine;
8 (44) Propiram;
9 (45) Racemoramide;
10 (45.1) Thiofentanyl
11 (N-phenyl-N-[1-(2-thienyl)ethyl-
12 4-piperidinyl]-propanamide);
13 (46) Tilidine;
14 (47) Trimeperidine;
15 (48) Beta-hydroxy-3-methylfentanyl (other name:
16 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
17 N-phenylpropanamide);
18 (49) Furanyl fentanyl (FU-F);
19 (50) Butyryl fentanyl;
20 (51) Valeryl fentanyl;
21 (52) Acetyl fentanyl;
22 (53) Beta-hydroxy-thiofentanyl;
23 (54) 3,4-dichloro-N-[2-
24 (dimethylamino)cyclohexyl]-N-
25 methylbenzamide (U-47700);
26 (55) 4-chloro-N-[1-[2-
HB4352 - 4 - LRB103 35349 RLC 65413 b
HB4352- 5 -LRB103 35349 RLC 65413 b HB4352 - 5 - LRB103 35349 RLC 65413 b
HB4352 - 5 - LRB103 35349 RLC 65413 b
1 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
2 benzenesulfonamide (W-18);
3 (56) 4-chloro-N-[1-(2-phenylethyl)
4 -2-piperidinylidene]-benzenesulfonamide (W-15);
5 (57) acrylfentanyl (acryloylfentanyl).
6 (c) Unless specifically excepted or unless listed in
7 another schedule, any of the following opium derivatives, its
8 salts, isomers and salts of isomers, whenever the existence of
9 such salts, isomers and salts of isomers is possible within
10 the specific chemical designation:
11 (1) Acetorphine;
12 (2) Acetyldihydrocodeine;
13 (3) Benzylmorphine;
14 (4) Codeine methylbromide;
15 (5) Codeine-N-Oxide;
16 (6) Cyprenorphine;
17 (7) Desomorphine;
18 (8) Diacetyldihydromorphine (Dihydroheroin);
19 (9) Dihydromorphine;
20 (10) Drotebanol;
21 (11) Etorphine (except hydrochloride salt);
22 (12) Heroin;
23 (13) Hydromorphinol;
24 (14) Methyldesorphine;
25 (15) Methyldihydromorphine;
26 (16) Morphine methylbromide;
HB4352 - 5 - LRB103 35349 RLC 65413 b
HB4352- 6 -LRB103 35349 RLC 65413 b HB4352 - 6 - LRB103 35349 RLC 65413 b
HB4352 - 6 - LRB103 35349 RLC 65413 b
1 (17) Morphine methylsulfonate;
2 (18) Morphine-N-Oxide;
3 (19) Myrophine;
4 (20) Nicocodeine;
5 (21) Nicomorphine;
6 (22) Normorphine;
7 (23) Pholcodine;
8 (24) Thebacon.
9 (d) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 hallucinogenic substances, or which contains any of its salts,
13 isomers and salts of isomers, whenever the existence of such
14 salts, isomers, and salts of isomers is possible within the
15 specific chemical designation (for the purposes of this
16 paragraph only, the term "isomer" includes the optical,
17 position and geometric isomers):
18 (1) 3,4-methylenedioxyamphetamine
19 (alpha-methyl,3,4-methylenedioxyphenethylamine,
20 methylenedioxyamphetamine, MDA);
21 (1.1) Alpha-ethyltryptamine
22 (some trade or other names: etryptamine;
23 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
24 3-(2-aminobutyl)indole; a-ET; and AET);
25 (2) 3,4-methylenedioxymethamphetamine (MDMA);
26 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
HB4352 - 6 - LRB103 35349 RLC 65413 b
HB4352- 7 -LRB103 35349 RLC 65413 b HB4352 - 7 - LRB103 35349 RLC 65413 b
HB4352 - 7 - LRB103 35349 RLC 65413 b
1 (also known as: N-ethyl-alpha-methyl-
2 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
3 and MDEA);
4 (2.2) N-Benzylpiperazine (BZP);
5 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
6 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
7 (4) 3,4,5-trimethoxyamphetamine (TMA);
8 (5) (Blank);
9 (6) Diethyltryptamine (DET);
10 (7) Dimethyltryptamine (DMT);
11 (7.1) 5-Methoxy-diallyltryptamine;
12 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
13 (9) Ibogaine (some trade and other names:
14 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
15 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
16 indole; Tabernanthe iboga);
17 (10) Lysergic acid diethylamide;
18 (10.1) Salvinorin A;
19 (10.5) Salvia divinorum (meaning all parts of the
20 plant presently classified botanically as Salvia
21 divinorum, whether growing or not, the seeds thereof, any
22 extract from any part of that plant, and every compound,
23 manufacture, salts, isomers, and salts of isomers whenever
24 the existence of such salts, isomers, and salts of isomers
25 is possible within the specific chemical designation,
26 derivative, mixture, or preparation of that plant, its
HB4352 - 7 - LRB103 35349 RLC 65413 b
HB4352- 8 -LRB103 35349 RLC 65413 b HB4352 - 8 - LRB103 35349 RLC 65413 b
HB4352 - 8 - LRB103 35349 RLC 65413 b
1 seeds or extracts);
2 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
3 (12) Peyote (meaning all parts of the plant presently
4 classified botanically as Lophophora williamsii Lemaire,
5 whether growing or not, the seeds thereof, any extract
6 from any part of that plant, and every compound,
7 manufacture, salts, derivative, mixture, or preparation of
8 that plant, its seeds or extracts);
9 (13) N-ethyl-3-piperidyl benzilate (JB 318);
10 (14) N-methyl-3-piperidyl benzilate;
11 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
12 (also known as N-hydroxy-alpha-methyl-
13 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
14 (15) Parahexyl; some trade or other names:
15 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
16 dibenzo (b,d) pyran; Synhexyl;
17 (16) Psilocybin;
18 (17) Psilocyn;
19 (18) Alpha-methyltryptamine (AMT);
20 (19) 2,5-dimethoxyamphetamine
21 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
22 (20) 4-bromo-2,5-dimethoxyamphetamine
23 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
24 4-bromo-2,5-DMA);
25 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
26 Some trade or other names: 2-(4-bromo-
HB4352 - 8 - LRB103 35349 RLC 65413 b
HB4352- 9 -LRB103 35349 RLC 65413 b HB4352 - 9 - LRB103 35349 RLC 65413 b
HB4352 - 9 - LRB103 35349 RLC 65413 b
1 2,5-dimethoxyphenyl)-1-aminoethane;
2 alpha-desmethyl DOB, 2CB, Nexus;
3 (21) 4-methoxyamphetamine
4 (4-methoxy-alpha-methylphenethylamine;
5 paramethoxyamphetamine; PMA);
6 (22) (Blank);
7 (23) Ethylamine analog of phencyclidine.
8 Some trade or other names:
9 N-ethyl-1-phenylcyclohexylamine,
10 (1-phenylcyclohexyl) ethylamine,
11 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
12 (24) Pyrrolidine analog of phencyclidine. Some trade
13 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
14 PHP;
15 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
16 (26) 2,5-dimethoxy-4-ethylamphetamine
17 (another name: DOET);
18 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
19 (another name: TCPy);
20 (28) (Blank);
21 (29) Thiophene analog of phencyclidine (some trade
22 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
23 2-thienyl analog of phencyclidine; TPCP; TCP);
24 (29.1) Benzothiophene analog of phencyclidine. Some
25 trade or other names: BTCP or benocyclidine;
26 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
HB4352 - 9 - LRB103 35349 RLC 65413 b
HB4352- 10 -LRB103 35349 RLC 65413 b HB4352 - 10 - LRB103 35349 RLC 65413 b
HB4352 - 10 - LRB103 35349 RLC 65413 b
1 (30) Bufotenine (some trade or other names:
2 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
3 3-(2-dimethylaminoethyl)-5-indolol;
4 5-hydroxy-N,N-dimethyltryptamine;
5 N,N-dimethylserotonin; mappine);
6 (31) (Blank);
7 (32) (Blank);
8 (33) (Blank);
9 (34) (Blank);
10 (34.5) (Blank);
11 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
12 (2-methyloctan-2-yl)-6a,7,
13 10,10a-tetrahydrobenzo[c]chromen-1-ol
14 Some trade or other names: HU-210;
15 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
16 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
17 tetrahydrobenzo[c]chromen-1-ol, its isomers,
18 salts, and salts of isomers; Some trade or other
19 names: HU-210, Dexanabinol;
20 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
21 6,6-dimethyl-3-(2-methyloctan-2-yl)-
22 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
23 Some trade or other names: HU-211;
24 (37) (Blank);
25 (38) (Blank);
26 (39) (Blank);
HB4352 - 10 - LRB103 35349 RLC 65413 b
HB4352- 11 -LRB103 35349 RLC 65413 b HB4352 - 11 - LRB103 35349 RLC 65413 b
HB4352 - 11 - LRB103 35349 RLC 65413 b
1 (40) (Blank);
2 (41) (Blank);
3 (42) Any compound structurally derived from
4 3-(1-naphthoyl)indole or
5 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
6 nitrogen atom of the indole ring by alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl whether or not further substituted
10 in the indole ring to any extent, whether or not
11 substituted in the naphthyl ring to any extent. Examples
12 of this structural class include, but are not limited to,
13 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
14 (43) Any compound structurally derived from
15 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
16 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further substituted
20 in the pyrrole ring to any extent, whether or not
21 substituted in the naphthyl ring to any extent. Examples
22 of this structural class include, but are not limited to,
23 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
24 (44) Any compound structurally derived from
25 1-(1-naphthylmethyl)indene by substitution at the
26 3-position of the indene ring by alkyl, haloalkyl,
HB4352 - 11 - LRB103 35349 RLC 65413 b
HB4352- 12 -LRB103 35349 RLC 65413 b HB4352 - 12 - LRB103 35349 RLC 65413 b
HB4352 - 12 - LRB103 35349 RLC 65413 b
1 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
2 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl whether or not further substituted
4 in the indene ring to any extent, whether or not
5 substituted in the naphthyl ring to any extent. Examples
6 of this structural class include, but are not limited to,
7 JWH-176;
8 (45) Any compound structurally derived from
9 3-phenylacetylindole by substitution at the nitrogen atom
10 of the indole ring with alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
12 halide, 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further substituted
14 in the indole ring to any extent, whether or not
15 substituted in the phenyl ring to any extent. Examples of
16 this structural class include, but are not limited to,
17 JWH-167, JWH-250, JWH-251, and RCS-8;
18 (46) Any compound structurally derived from
19 2-(3-hydroxycyclohexyl)phenol by substitution at the
20 5-position of the phenolic ring by alkyl, haloalkyl,
21 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
22 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not substituted in the
24 cyclohexyl ring to any extent. Examples of this structural
25 class include, but are not limited to, CP 47, 497 and its
26 C8 homologue (cannabicyclohexanol);
HB4352 - 12 - LRB103 35349 RLC 65413 b
HB4352- 13 -LRB103 35349 RLC 65413 b HB4352 - 13 - LRB103 35349 RLC 65413 b
HB4352 - 13 - LRB103 35349 RLC 65413 b
1 (46.1) Any compound structurally derived from
2 3-(benzoyl) indole with substitution at the nitrogen atom
3 of the indole ring by an alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl group whether or not further
7 substituted in the indole ring to any extent and whether
8 or not substituted in the phenyl ring to any extent.
9 Examples of this structural class include, but are not
10 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
11 48,098), and RCS-4;
12 (47) (Blank);
13 (48) (Blank);
14 (49) (Blank);
15 (50) (Blank);
16 (51) (Blank);
17 (52) (Blank);
18 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
19 Some trade or other names: 2C-T-7;
20 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
21 trade or other names: 2C-E;
22 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
23 trade or other names: 2C-D;
24 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
25 trade or other names: 2C-C;
26 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
HB4352 - 13 - LRB103 35349 RLC 65413 b
HB4352- 14 -LRB103 35349 RLC 65413 b HB4352 - 14 - LRB103 35349 RLC 65413 b
HB4352 - 14 - LRB103 35349 RLC 65413 b
1 or other names: 2C-I;
2 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
3 trade or other names: 2C-T-2;
4 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
5 Some trade or other names: 2C-T-4;
6 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
7 other names: 2C-H;
8 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
9 trade or other names: 2C-N;
10 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
11 trade or other names: 2C-P;
12 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
13 Some trade or other names: 2C-G;
14 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
15 phenethylamine referred to in subparagraphs (20.1), (53),
16 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
17 (53.8), (53.9), and (53.10) including, but not limited to,
18 25I-NBOMe and 25C-NBOMe;
19 (54) 5-Methoxy-N,N-diisopropyltryptamine;
20 (55) (Blank);
21 (56) (Blank);
22 (57) (Blank);
23 (58) (Blank);
24 (59) 3-cyclopropoylindole with substitution at the
25 nitrogen atom of the indole ring by alkyl, haloalkyl,
26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
HB4352 - 14 - LRB103 35349 RLC 65413 b
HB4352- 15 -LRB103 35349 RLC 65413 b HB4352 - 15 - LRB103 35349 RLC 65413 b
HB4352 - 15 - LRB103 35349 RLC 65413 b
1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further substituted
3 on the indole ring to any extent, whether or not
4 substituted on the cyclopropyl ring to any extent:
5 including, but not limited to, XLR11, UR144, FUB-144;
6 (60) 3-adamantoylindole with substitution at the
7 nitrogen atom of the indole ring by alkyl, haloalkyl,
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further substituted
11 on the indole ring to any extent, whether or not
12 substituted on the adamantyl ring to any extent:
13 including, but not limited to, AB-001;
14 (61) N-(adamantyl)-indole-3-carboxamide with
15 substitution at the nitrogen atom of the indole ring by
16 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
17 cycloalkylethyl, aryl halide, alkyl aryl halide,
18 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further substituted
20 on the indole ring to any extent, whether or not
21 substituted on the adamantyl ring to any extent:
22 including, but not limited to, APICA/2NE-1, STS-135;
23 (62) N-(adamantyl)-indazole-3-carboxamide with
24 substitution at a nitrogen atom of the indazole ring by
25 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
26 cycloalkylethyl, aryl halide, alkyl aryl halide,
HB4352 - 15 - LRB103 35349 RLC 65413 b
HB4352- 16 -LRB103 35349 RLC 65413 b HB4352 - 16 - LRB103 35349 RLC 65413 b
HB4352 - 16 - LRB103 35349 RLC 65413 b
1 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further substituted
3 on the indazole ring to any extent, whether or not
4 substituted on the adamantyl ring to any extent:
5 including, but not limited to, AKB48, 5F-AKB48;
6 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
7 with substitution at the nitrogen atom of the indole ring
8 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
9 cycloalkylethyl, aryl halide, alkyl aryl halide,
10 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl, whether or not further substituted
12 on the indole ring to any extent, whether or not
13 substituted on the quinoline ring to any extent:
14 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
15 (64) 3-(1-naphthoyl)indazole with substitution at the
16 nitrogen atom of the indazole ring by alkyl, haloalkyl,
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
18 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further substituted
20 on the indazole ring to any extent, whether or not
21 substituted on the naphthyl ring to any extent: including,
22 but not limited to, THJ-018, THJ-2201;
23 (65) 2-(1-naphthoyl)benzimidazole with substitution
24 at the nitrogen atom of the benzimidazole ring by alkyl,
25 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
26 aryl halide, alkyl aryl halide,
HB4352 - 16 - LRB103 35349 RLC 65413 b
HB4352- 17 -LRB103 35349 RLC 65413 b HB4352 - 17 - LRB103 35349 RLC 65413 b
HB4352 - 17 - LRB103 35349 RLC 65413 b
1 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further substituted
3 on the benzimidazole ring to any extent, whether or not
4 substituted on the naphthyl ring to any extent: including,
5 but not limited to, FUBIMINA;
6 (66)
7 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
8 3-carboxamide with substitution on the nitrogen atom of
9 the indazole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further substituted
13 on the indazole ring to any extent: including, but not
14 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
15 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
16 indazole-3-carboxamide with substitution on the nitrogen
17 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
18 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
19 halide, 1-(N-methyl-2-piperidinyl)methyl, or
20 2-(4-morpholinyl)ethyl, whether or not further substituted
21 on the indazole ring to any extent: including, but not
22 limited to, ADB-PINACA, ADB-FUBINACA;
23 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
24 indole-3-carboxamide with substitution on the nitrogen
25 atom of the indole ring by alkyl, haloalkyl, alkenyl,
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
HB4352 - 17 - LRB103 35349 RLC 65413 b
HB4352- 18 -LRB103 35349 RLC 65413 b HB4352 - 18 - LRB103 35349 RLC 65413 b
HB4352 - 18 - LRB103 35349 RLC 65413 b
1 halide, 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further substituted
3 on the indole ring to any extent: including, but not
4 limited to, ADBICA, 5F-ADBICA;
5 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
6 3-carboxamide with substitution on the nitrogen atom of
7 the indole ring by alkyl, haloalkyl, alkenyl,
8 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
9 halide, 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further substituted
11 on the indole ring to any extent: including, but not
12 limited to, ABICA, 5F-ABICA;
13 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
14 methylbutanoate with substitution on the nitrogen atom of
15 the indazole ring by alkyl, haloalkyl, alkenyl,
16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17 halide, 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 on the indazole ring to any extent: including, but not
20 limited to, AMB, 5F-AMB;
21 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
22 dimethylbutanoate with substitution on the nitrogen atom
23 of the indazole ring by alkyl, haloalkyl, alkenyl,
24 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
25 halide, 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further substituted
HB4352 - 18 - LRB103 35349 RLC 65413 b
HB4352- 19 -LRB103 35349 RLC 65413 b HB4352 - 19 - LRB103 35349 RLC 65413 b
HB4352 - 19 - LRB103 35349 RLC 65413 b
1 on the indazole ring to any extent: including, but not
2 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
3 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
4 methylbutanoate with substitution on the nitrogen atom of
5 the indole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indazole ring to any extent: including, but not
10 limited to, MMB018, MMB2201, and AMB-CHMICA;
11 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
12 dimethylbutanoate with substitution on the nitrogen atom
13 of the indole ring by alkyl, haloalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not further substituted
17 on the indazole ring to any extent: including, but not
18 limited to, MDMB-CHMICA;
19 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
20 indazole-3-carboxamide with substitution on the nitrogen
21 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further substituted
25 on the indazole ring to any extent: including, but not
26 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
HB4352 - 19 - LRB103 35349 RLC 65413 b
HB4352- 20 -LRB103 35349 RLC 65413 b HB4352 - 20 - LRB103 35349 RLC 65413 b
HB4352 - 20 - LRB103 35349 RLC 65413 b
1 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
2 3-carboxamide with substitution on the nitrogen atom of
3 the indole ring by alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the indazole ring to any extent: including, but not
8 limited to, APP-PICA and 5-fluoro-APP-PICA;
9 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
10 4-AcO-DMT;
11 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
12 name 5-MeO-MIPT;
13 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
14 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
15 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
16 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
17 (4-HO-MiPT);
18 (82) Fluorophenylpiperazine;
19 (83) Methoxetamine;
20 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
21 ethcathinone).
22 (e) Unless specifically excepted or unless listed in
23 another schedule, any material, compound, mixture, or
24 preparation which contains any quantity of the following
25 substances having a depressant effect on the central nervous
26 system, including its salts, isomers, and salts of isomers
HB4352 - 20 - LRB103 35349 RLC 65413 b
HB4352- 21 -LRB103 35349 RLC 65413 b HB4352 - 21 - LRB103 35349 RLC 65413 b
HB4352 - 21 - LRB103 35349 RLC 65413 b
1 whenever the existence of such salts, isomers, and salts of
2 isomers is possible within the specific chemical designation:
3 (1) mecloqualone;
4 (2) methaqualone; and
5 (3) gamma hydroxybutyric acid.
6 (f) Unless specifically excepted or unless listed in
7 another schedule, any material, compound, mixture, or
8 preparation which contains any quantity of the following
9 substances having a stimulant effect on the central nervous
10 system, including its salts, isomers, and salts of isomers:
11 (1) Fenethylline;
12 (2) N-ethylamphetamine;
13 (3) Aminorex (some other names:
14 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
15 4-5-dihydro-5-phenyl-2-oxazolamine) and its
16 salts, optical isomers, and salts of optical isomers;
17 (4) Methcathinone (some other names:
18 2-methylamino-1-phenylpropan-1-one;
19 Ephedrone; 2-(methylamino)-propiophenone;
20 alpha-(methylamino)propiophenone; N-methylcathinone;
21 methycathinone; Monomethylpropion; UR 1431) and its
22 salts, optical isomers, and salts of optical isomers;
23 (5) Cathinone (some trade or other names:
24 2-aminopropiophenone; alpha-aminopropiophenone;
25 2-amino-1-phenyl-propanone; norephedrone);
26 (6) N,N-dimethylamphetamine (also known as:
HB4352 - 21 - LRB103 35349 RLC 65413 b
HB4352- 22 -LRB103 35349 RLC 65413 b HB4352 - 22 - LRB103 35349 RLC 65413 b
HB4352 - 22 - LRB103 35349 RLC 65413 b
1 N,N-alpha-trimethyl-benzeneethanamine;
2 N,N-alpha-trimethylphenethylamine);
3 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
4 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
5 (8) 3,4-Methylenedioxypyrovalerone (MDPV);
6 (9) Halogenated amphetamines and
7 methamphetamines - any compound derived from either
8 amphetamine or methamphetamine through the substitution
9 of a halogen on the phenyl ring, including, but not
10 limited to, 2-fluoroamphetamine, 3-
11 fluoroamphetamine and 4-fluoroamphetamine;
12 (10) Aminopropylbenzofuran (APB):
13 including 4-(2-Aminopropyl) benzofuran, 5-
14 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
15 benzofuran, and 7-(2-Aminopropyl) benzofuran;
16 (11) Aminopropyldihydrobenzofuran (APDB):
17 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
18 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
19 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
20 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
21 (12) Methylaminopropylbenzofuran
22 (MAPB): including 4-(2-methylaminopropyl)
23 benzofuran, 5-(2-methylaminopropyl)benzofuran,
24 6-(2-methylaminopropyl)benzofuran
25 and 7-(2-methylaminopropyl)benzofuran.
26 (g) Temporary listing of substances subject to emergency
HB4352 - 22 - LRB103 35349 RLC 65413 b
HB4352- 23 -LRB103 35349 RLC 65413 b HB4352 - 23 - LRB103 35349 RLC 65413 b
HB4352 - 23 - LRB103 35349 RLC 65413 b
1 scheduling. Any material, compound, mixture, or preparation
2 that contains any quantity of the following substances:
3 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
4 (benzylfentanyl), its optical isomers, isomers, salts, and
5 salts of isomers;
6 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
7 phenylpropanamide (thenylfentanyl), its optical isomers,
8 salts, and salts of isomers.
9 (h) Synthetic cathinones. Unless specifically excepted,
10 any chemical compound which is not approved by the United
11 States Food and Drug Administration or, if approved, is not
12 dispensed or possessed in accordance with State or federal
13 law, not including bupropion, structurally derived from
14 2-aminopropan-1-one by substitution at the 1-position with
15 either phenyl, naphthyl, or thiophene ring systems, whether or
16 not the compound is further modified in one or more of the
17 following ways:
18 (1) by substitution in the ring system to any extent
19 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
20 halide substituents, whether or not further substituted in
21 the ring system by one or more other univalent
22 substituents. Examples of this class include, but are not
23 limited to, 3,4-Methylenedioxycathinone (bk-MDA);
24 (2) by substitution at the 3-position with an acyclic
25 alkyl substituent. Examples of this class include, but are
26 not limited to, 2-methylamino-1-phenylbutan-1-one
HB4352 - 23 - LRB103 35349 RLC 65413 b
HB4352- 24 -LRB103 35349 RLC 65413 b HB4352 - 24 - LRB103 35349 RLC 65413 b
HB4352 - 24 - LRB103 35349 RLC 65413 b
1 (buphedrone); or
2 (3) by substitution at the 2-amino nitrogen atom with
3 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
4 inclusion of the 2-amino nitrogen atom in a cyclic
5 structure. Examples of this class include, but are not
6 limited to, Dimethylcathinone, Ethcathinone, and
7 a-Pyrrolidinopropiophenone (a-PPP); or
8 Any other synthetic cathinone which is not approved by the
9 United States Food and Drug Administration or, if approved, is
10 not dispensed or possessed in accordance with State or federal
11 law.
12 (i) Synthetic cannabinoids or piperazines. Any synthetic
13 cannabinoid or piperazine which is not approved by the United
14 States Food and Drug Administration or, if approved, which is
15 not dispensed or possessed in accordance with State and
16 federal law.
17 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
18 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
19 8-14-18.)
20 (Text of Section after amendment by P.A. 103-245)
21 Sec. 204. (a) The controlled substances listed in this
22 Section are included in Schedule I.
23 (b) Unless specifically excepted or unless listed in
24 another schedule, any of the following opiates, including
25 their isomers, esters, ethers, salts, and salts of isomers,
HB4352 - 24 - LRB103 35349 RLC 65413 b
HB4352- 25 -LRB103 35349 RLC 65413 b HB4352 - 25 - LRB103 35349 RLC 65413 b
HB4352 - 25 - LRB103 35349 RLC 65413 b
1 esters, and ethers, whenever the existence of such isomers,
2 esters, ethers and salts is possible within the specific
3 chemical designation:
4 (1) Acetylmethadol;
5 (1.1) Acetyl-alpha-methylfentanyl
6 (N-[1-(1-methyl-2-phenethyl)-
7 4-piperidinyl]-N-phenylacetamide);
8 (2) Allylprodine;
9 (3) Alphacetylmethadol, except
10 levo-alphacetylmethadol (also known as levo-alpha-
11 acetylmethadol, levomethadyl acetate, or LAAM);
12 (4) Alphameprodine;
13 (5) Alphamethadol;
14 (6) Alpha-methylfentanyl
15 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
16 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
17 propanilido) piperidine;
18 (6.1) Alpha-methylthiofentanyl
19 (N-[1-methyl-2-(2-thienyl)ethyl-
20 4-piperidinyl]-N-phenylpropanamide);
21 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
22 (7.1) PEPAP
23 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
24 (8) Benzethidine;
25 (9) Betacetylmethadol;
26 (9.1) Beta-hydroxyfentanyl
HB4352 - 25 - LRB103 35349 RLC 65413 b
HB4352- 26 -LRB103 35349 RLC 65413 b HB4352 - 26 - LRB103 35349 RLC 65413 b
HB4352 - 26 - LRB103 35349 RLC 65413 b
1 (N-[1-(2-hydroxy-2-phenethyl)-
2 4-piperidinyl]-N-phenylpropanamide);
3 (10) Betameprodine;
4 (11) Betamethadol;
5 (12) Betaprodine;
6 (13) Clonitazene;
7 (14) Dextromoramide;
8 (15) Diampromide;
9 (16) Diethylthiambutene;
10 (17) Difenoxin;
11 (18) Dimenoxadol;
12 (19) Dimepheptanol;
13 (20) Dimethylthiambutene;
14 (21) Dioxaphetylbutyrate;
15 (22) Dipipanone;
16 (23) Ethylmethylthiambutene;
17 (24) Etonitazene;
18 (25) Etoxeridine;
19 (26) Furethidine;
20 (27) Hydroxpethidine;
21 (28) Ketobemidone;
22 (29) Levomoramide;
23 (30) Levophenacylmorphan;
24 (31) 3-Methylfentanyl
25 (N-[3-methyl-1-(2-phenylethyl)-
26 4-piperidyl]-N-phenylpropanamide);
HB4352 - 26 - LRB103 35349 RLC 65413 b
HB4352- 27 -LRB103 35349 RLC 65413 b HB4352 - 27 - LRB103 35349 RLC 65413 b
HB4352 - 27 - LRB103 35349 RLC 65413 b
1 (31.1) 3-Methylthiofentanyl
2 (N-[(3-methyl-1-(2-thienyl)ethyl-
3 4-piperidinyl]-N-phenylpropanamide);
4 (32) Morpheridine;
5 (33) Noracymethadol;
6 (34) Norlevorphanol;
7 (35) Normethadone;
8 (36) Norpipanone;
9 (36.1) Para-fluorofentanyl
10 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
11 4-piperidinyl]propanamide);
12 (37) Phenadoxone;
13 (38) Phenampromide;
14 (39) Phenomorphan;
15 (40) Phenoperidine;
16 (41) Piritramide;
17 (42) Proheptazine;
18 (43) Properidine;
19 (44) Propiram;
20 (45) Racemoramide;
21 (45.1) Thiofentanyl
22 (N-phenyl-N-[1-(2-thienyl)ethyl-
23 4-piperidinyl]-propanamide);
24 (46) Tilidine;
25 (47) Trimeperidine;
26 (48) Beta-hydroxy-3-methylfentanyl (other name:
HB4352 - 27 - LRB103 35349 RLC 65413 b
HB4352- 28 -LRB103 35349 RLC 65413 b HB4352 - 28 - LRB103 35349 RLC 65413 b
HB4352 - 28 - LRB103 35349 RLC 65413 b
1 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
2 N-phenylpropanamide);
3 (49) Furanyl fentanyl (FU-F);
4 (50) Butyryl fentanyl;
5 (51) Valeryl fentanyl;
6 (52) Acetyl fentanyl;
7 (53) Beta-hydroxy-thiofentanyl;
8 (54) 3,4-dichloro-N-[2-
9 (dimethylamino)cyclohexyl]-N-
10 methylbenzamide (U-47700);
11 (55) 4-chloro-N-[1-[2-
12 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
13 benzenesulfonamide (W-18);
14 (56) 4-chloro-N-[1-(2-phenylethyl)
15 -2-piperidinylidene]-benzenesulfonamide (W-15);
16 (57) acrylfentanyl (acryloylfentanyl).
17 (c) Unless specifically excepted or unless listed in
18 another schedule, any of the following opium derivatives, its
19 salts, isomers and salts of isomers, whenever the existence of
20 such salts, isomers and salts of isomers is possible within
21 the specific chemical designation:
22 (1) Acetorphine;
23 (2) Acetyldihydrocodeine;
24 (3) Benzylmorphine;
25 (4) Codeine methylbromide;
26 (5) Codeine-N-Oxide;
HB4352 - 28 - LRB103 35349 RLC 65413 b
HB4352- 29 -LRB103 35349 RLC 65413 b HB4352 - 29 - LRB103 35349 RLC 65413 b
HB4352 - 29 - LRB103 35349 RLC 65413 b
1 (6) Cyprenorphine;
2 (7) Desomorphine;
3 (8) Diacetyldihydromorphine (Dihydroheroin);
4 (9) Dihydromorphine;
5 (10) Drotebanol;
6 (11) Etorphine (except hydrochloride salt);
7 (12) Heroin;
8 (13) Hydromorphinol;
9 (14) Methyldesorphine;
10 (15) Methyldihydromorphine;
11 (16) Morphine methylbromide;
12 (17) Morphine methylsulfonate;
13 (18) Morphine-N-Oxide;
14 (19) Myrophine;
15 (20) Nicocodeine;
16 (21) Nicomorphine;
17 (22) Normorphine;
18 (23) Pholcodine;
19 (24) Thebacon.
20 (d) Unless specifically excepted or unless listed in
21 another schedule, any material, compound, mixture, or
22 preparation which contains any quantity of the following
23 hallucinogenic substances, or which contains any of its salts,
24 isomers and salts of isomers, whenever the existence of such
25 salts, isomers, and salts of isomers is possible within the
26 specific chemical designation (for the purposes of this
HB4352 - 29 - LRB103 35349 RLC 65413 b
HB4352- 30 -LRB103 35349 RLC 65413 b HB4352 - 30 - LRB103 35349 RLC 65413 b
HB4352 - 30 - LRB103 35349 RLC 65413 b
1 paragraph only, the term "isomer" includes the optical,
2 position and geometric isomers):
3 (1) 3,4-methylenedioxyamphetamine
4 (alpha-methyl,3,4-methylenedioxyphenethylamine,
5 methylenedioxyamphetamine, MDA);
6 (1.1) Alpha-ethyltryptamine
7 (some trade or other names: etryptamine;
8 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
9 3-(2-aminobutyl)indole; a-ET; and AET);
10 (2) 3,4-methylenedioxymethamphetamine (MDMA);
11 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
12 (also known as: N-ethyl-alpha-methyl-
13 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
14 and MDEA);
15 (2.2) N-Benzylpiperazine (BZP);
16 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
17 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
18 (4) 3,4,5-trimethoxyamphetamine (TMA);
19 (5) (Blank);
20 (6) Diethyltryptamine (DET);
21 (7) Dimethyltryptamine (DMT);
22 (7.1) 5-Methoxy-diallyltryptamine;
23 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
24 (9) Ibogaine (some trade and other names:
25 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
26 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
HB4352 - 30 - LRB103 35349 RLC 65413 b
HB4352- 31 -LRB103 35349 RLC 65413 b HB4352 - 31 - LRB103 35349 RLC 65413 b
HB4352 - 31 - LRB103 35349 RLC 65413 b
1 indole; Tabernanthe iboga);
2 (10) Lysergic acid diethylamide;
3 (10.1) Salvinorin A;
4 (10.5) Salvia divinorum (meaning all parts of the
5 plant presently classified botanically as Salvia
6 divinorum, whether growing or not, the seeds thereof, any
7 extract from any part of that plant, and every compound,
8 manufacture, salts, isomers, and salts of isomers whenever
9 the existence of such salts, isomers, and salts of isomers
10 is possible within the specific chemical designation,
11 derivative, mixture, or preparation of that plant, its
12 seeds or extracts);
13 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
14 (12) Peyote (meaning all parts of the plant presently
15 classified botanically as Lophophora williamsii Lemaire,
16 whether growing or not, the seeds thereof, any extract
17 from any part of that plant, and every compound,
18 manufacture, salts, derivative, mixture, or preparation of
19 that plant, its seeds or extracts);
20 (13) N-ethyl-3-piperidyl benzilate (JB 318);
21 (14) N-methyl-3-piperidyl benzilate;
22 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
23 (also known as N-hydroxy-alpha-methyl-
24 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
25 (15) Parahexyl; some trade or other names:
26 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
HB4352 - 31 - LRB103 35349 RLC 65413 b
HB4352- 32 -LRB103 35349 RLC 65413 b HB4352 - 32 - LRB103 35349 RLC 65413 b
HB4352 - 32 - LRB103 35349 RLC 65413 b
1 dibenzo (b,d) pyran; Synhexyl;
2 (16) Psilocybin;
3 (17) Psilocyn;
4 (18) Alpha-methyltryptamine (AMT);
5 (19) 2,5-dimethoxyamphetamine
6 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
7 (20) 4-bromo-2,5-dimethoxyamphetamine
8 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
9 4-bromo-2,5-DMA);
10 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
11 Some trade or other names: 2-(4-bromo-
12 2,5-dimethoxyphenyl)-1-aminoethane;
13 alpha-desmethyl DOB, 2CB, Nexus;
14 (21) 4-methoxyamphetamine
15 (4-methoxy-alpha-methylphenethylamine;
16 paramethoxyamphetamine; PMA);
17 (22) (Blank);
18 (23) Ethylamine analog of phencyclidine.
19 Some trade or other names:
20 N-ethyl-1-phenylcyclohexylamine,
21 (1-phenylcyclohexyl) ethylamine,
22 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
23 (24) Pyrrolidine analog of phencyclidine. Some trade
24 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
25 PHP;
26 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
HB4352 - 32 - LRB103 35349 RLC 65413 b
HB4352- 33 -LRB103 35349 RLC 65413 b HB4352 - 33 - LRB103 35349 RLC 65413 b
HB4352 - 33 - LRB103 35349 RLC 65413 b
1 (26) 2,5-dimethoxy-4-ethylamphetamine
2 (another name: DOET);
3 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
4 (another name: TCPy);
5 (28) (Blank);
6 (29) Thiophene analog of phencyclidine (some trade
7 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
8 2-thienyl analog of phencyclidine; TPCP; TCP);
9 (29.1) Benzothiophene analog of phencyclidine. Some
10 trade or other names: BTCP or benocyclidine;
11 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
12 (30) Bufotenine (some trade or other names:
13 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
14 3-(2-dimethylaminoethyl)-5-indolol;
15 5-hydroxy-N,N-dimethyltryptamine;
16 N,N-dimethylserotonin; mappine);
17 (31) (Blank);
18 (32) (Blank);
19 (33) (Blank);
20 (34) (Blank);
21 (34.5) (Blank);
22 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
23 (2-methyloctan-2-yl)-6a,7,
24 10,10a-tetrahydrobenzo[c]chromen-1-ol
25 Some trade or other names: HU-210;
26 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
HB4352 - 33 - LRB103 35349 RLC 65413 b
HB4352- 34 -LRB103 35349 RLC 65413 b HB4352 - 34 - LRB103 35349 RLC 65413 b
HB4352 - 34 - LRB103 35349 RLC 65413 b
1 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
2 tetrahydrobenzo[c]chromen-1-ol, its isomers,
3 salts, and salts of isomers; Some trade or other
4 names: HU-210, Dexanabinol;
5 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
6 6,6-dimethyl-3-(2-methyloctan-2-yl)-
7 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
8 Some trade or other names: HU-211;
9 (37) (Blank);
10 (38) (Blank);
11 (39) (Blank);
12 (40) (Blank);
13 (41) (Blank);
14 (42) Any compound structurally derived from
15 3-(1-naphthoyl)indole or
16 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
17 nitrogen atom of the indole ring by alkyl, haloalkyl,
18 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
19 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
20 2-(4-morpholinyl)ethyl whether or not further substituted
21 in the indole ring to any extent, whether or not
22 substituted in the naphthyl ring to any extent. Examples
23 of this structural class include, but are not limited to,
24 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
25 (43) Any compound structurally derived from
26 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
HB4352 - 34 - LRB103 35349 RLC 65413 b
HB4352- 35 -LRB103 35349 RLC 65413 b HB4352 - 35 - LRB103 35349 RLC 65413 b
HB4352 - 35 - LRB103 35349 RLC 65413 b
1 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3 halide, 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl, whether or not further substituted
5 in the pyrrole ring to any extent, whether or not
6 substituted in the naphthyl ring to any extent. Examples
7 of this structural class include, but are not limited to,
8 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
9 (44) Any compound structurally derived from
10 1-(1-naphthylmethyl)indene by substitution at the
11 3-position of the indene ring by alkyl, haloalkyl,
12 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
13 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl whether or not further substituted
15 in the indene ring to any extent, whether or not
16 substituted in the naphthyl ring to any extent. Examples
17 of this structural class include, but are not limited to,
18 JWH-176;
19 (45) Any compound structurally derived from
20 3-phenylacetylindole by substitution at the nitrogen atom
21 of the indole ring with alkyl, haloalkyl, alkenyl,
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further substituted
25 in the indole ring to any extent, whether or not
26 substituted in the phenyl ring to any extent. Examples of
HB4352 - 35 - LRB103 35349 RLC 65413 b
HB4352- 36 -LRB103 35349 RLC 65413 b HB4352 - 36 - LRB103 35349 RLC 65413 b
HB4352 - 36 - LRB103 35349 RLC 65413 b
1 this structural class include, but are not limited to,
2 JWH-167, JWH-250, JWH-251, and RCS-8;
3 (46) Any compound structurally derived from
4 2-(3-hydroxycyclohexyl)phenol by substitution at the
5 5-position of the phenolic ring by alkyl, haloalkyl,
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not substituted in the
9 cyclohexyl ring to any extent. Examples of this structural
10 class include, but are not limited to, CP 47, 497 and its
11 C8 homologue (cannabicyclohexanol);
12 (46.1) Any compound structurally derived from
13 3-(benzoyl) indole with substitution at the nitrogen atom
14 of the indole ring by an alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl group whether or not further
18 substituted in the indole ring to any extent and whether
19 or not substituted in the phenyl ring to any extent.
20 Examples of this structural class include, but are not
21 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
22 48,098), and RCS-4;
23 (47) (Blank);
24 (48) (Blank);
25 (49) (Blank);
26 (50) (Blank);
HB4352 - 36 - LRB103 35349 RLC 65413 b
HB4352- 37 -LRB103 35349 RLC 65413 b HB4352 - 37 - LRB103 35349 RLC 65413 b
HB4352 - 37 - LRB103 35349 RLC 65413 b
1 (51) (Blank);
2 (52) (Blank);
3 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
4 Some trade or other names: 2C-T-7;
5 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
6 trade or other names: 2C-E;
7 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
8 trade or other names: 2C-D;
9 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
10 trade or other names: 2C-C;
11 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
12 or other names: 2C-I;
13 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
14 trade or other names: 2C-T-2;
15 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
16 Some trade or other names: 2C-T-4;
17 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
18 other names: 2C-H;
19 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
20 trade or other names: 2C-N;
21 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
22 trade or other names: 2C-P;
23 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
24 Some trade or other names: 2C-G;
25 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
26 phenethylamine referred to in subparagraphs (20.1), (53),
HB4352 - 37 - LRB103 35349 RLC 65413 b
HB4352- 38 -LRB103 35349 RLC 65413 b HB4352 - 38 - LRB103 35349 RLC 65413 b
HB4352 - 38 - LRB103 35349 RLC 65413 b
1 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
2 (53.8), (53.9), and (53.10) including, but not limited to,
3 25I-NBOMe and 25C-NBOMe;
4 (54) 5-Methoxy-N,N-diisopropyltryptamine;
5 (55) (Blank);
6 (56) (Blank);
7 (57) (Blank);
8 (58) (Blank);
9 (59) 3-cyclopropoylindole with substitution at the
10 nitrogen atom of the indole ring by alkyl, haloalkyl,
11 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
12 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further substituted
14 on the indole ring to any extent, whether or not
15 substituted on the cyclopropyl ring to any extent:
16 including, but not limited to, XLR11, UR144, FUB-144;
17 (60) 3-adamantoylindole with substitution at the
18 nitrogen atom of the indole ring by alkyl, haloalkyl,
19 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
20 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not further substituted
22 on the indole ring to any extent, whether or not
23 substituted on the adamantyl ring to any extent:
24 including, but not limited to, AB-001;
25 (61) N-(adamantyl)-indole-3-carboxamide with
26 substitution at the nitrogen atom of the indole ring by
HB4352 - 38 - LRB103 35349 RLC 65413 b
HB4352- 39 -LRB103 35349 RLC 65413 b HB4352 - 39 - LRB103 35349 RLC 65413 b
HB4352 - 39 - LRB103 35349 RLC 65413 b
1 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
2 cycloalkylethyl, aryl halide, alkyl aryl halide,
3 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl, whether or not further substituted
5 on the indole ring to any extent, whether or not
6 substituted on the adamantyl ring to any extent:
7 including, but not limited to, APICA/2NE-1, STS-135;
8 (62) N-(adamantyl)-indazole-3-carboxamide with
9 substitution at a nitrogen atom of the indazole ring by
10 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
11 cycloalkylethyl, aryl halide, alkyl aryl halide,
12 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further substituted
14 on the indazole ring to any extent, whether or not
15 substituted on the adamantyl ring to any extent:
16 including, but not limited to, AKB48, 5F-AKB48;
17 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
18 with substitution at the nitrogen atom of the indole ring
19 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20 cycloalkylethyl, aryl halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further substituted
23 on the indole ring to any extent, whether or not
24 substituted on the quinoline ring to any extent:
25 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
26 (64) 3-(1-naphthoyl)indazole with substitution at the
HB4352 - 39 - LRB103 35349 RLC 65413 b
HB4352- 40 -LRB103 35349 RLC 65413 b HB4352 - 40 - LRB103 35349 RLC 65413 b
HB4352 - 40 - LRB103 35349 RLC 65413 b
1 nitrogen atom of the indazole ring by alkyl, haloalkyl,
2 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
3 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl, whether or not further substituted
5 on the indazole ring to any extent, whether or not
6 substituted on the naphthyl ring to any extent: including,
7 but not limited to, THJ-018, THJ-2201;
8 (65) 2-(1-naphthoyl)benzimidazole with substitution
9 at the nitrogen atom of the benzimidazole ring by alkyl,
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
11 aryl halide, alkyl aryl halide,
12 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further substituted
14 on the benzimidazole ring to any extent, whether or not
15 substituted on the naphthyl ring to any extent: including,
16 but not limited to, FUBIMINA;
17 (66)
18 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
19 3-carboxamide with substitution on the nitrogen atom of
20 the indazole ring by alkyl, haloalkyl, alkenyl,
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22 halide, 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indazole ring to any extent: including, but not
25 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
26 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
HB4352 - 40 - LRB103 35349 RLC 65413 b
HB4352- 41 -LRB103 35349 RLC 65413 b HB4352 - 41 - LRB103 35349 RLC 65413 b
HB4352 - 41 - LRB103 35349 RLC 65413 b
1 indazole-3-carboxamide with substitution on the nitrogen
2 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further substituted
6 on the indazole ring to any extent: including, but not
7 limited to, ADB-PINACA, ADB-FUBINACA;
8 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
9 indole-3-carboxamide with substitution on the nitrogen
10 atom of the indole ring by alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
12 halide, 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further substituted
14 on the indole ring to any extent: including, but not
15 limited to, ADBICA, 5F-ADBICA;
16 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
17 3-carboxamide with substitution on the nitrogen atom of
18 the indole ring by alkyl, haloalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20 halide, 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not further substituted
22 on the indole ring to any extent: including, but not
23 limited to, ABICA, 5F-ABICA;
24 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
25 methylbutanoate with substitution on the nitrogen atom of
26 the indazole ring by alkyl, haloalkyl, alkenyl,
HB4352 - 41 - LRB103 35349 RLC 65413 b
HB4352- 42 -LRB103 35349 RLC 65413 b HB4352 - 42 - LRB103 35349 RLC 65413 b
HB4352 - 42 - LRB103 35349 RLC 65413 b
1 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
2 halide, 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl, whether or not further substituted
4 on the indazole ring to any extent: including, but not
5 limited to, AMB, 5F-AMB;
6 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
7 dimethylbutanoate with substitution on the nitrogen atom
8 of the indazole ring by alkyl, haloalkyl, alkenyl,
9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10 halide, 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl, whether or not further substituted
12 on the indazole ring to any extent: including, but not
13 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
14 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
15 methylbutanoate with substitution on the nitrogen atom of
16 the indole ring by alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further substituted
20 on the indazole ring to any extent: including, but not
21 limited to, MMB018, MMB2201, and AMB-CHMICA;
22 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
23 dimethylbutanoate with substitution on the nitrogen atom
24 of the indole ring by alkyl, haloalkyl, alkenyl,
25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26 halide, 1-(N-methyl-2-piperidinyl)methyl, or
HB4352 - 42 - LRB103 35349 RLC 65413 b
HB4352- 43 -LRB103 35349 RLC 65413 b HB4352 - 43 - LRB103 35349 RLC 65413 b
HB4352 - 43 - LRB103 35349 RLC 65413 b
1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the indazole ring to any extent: including, but not
3 limited to, MDMB-CHMICA;
4 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
5 indazole-3-carboxamide with substitution on the nitrogen
6 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8 halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further substituted
10 on the indazole ring to any extent: including, but not
11 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
12 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
13 3-carboxamide with substitution on the nitrogen atom of
14 the indole ring by alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indazole ring to any extent: including, but not
19 limited to, APP-PICA and 5-fluoro-APP-PICA;
20 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
21 4-AcO-DMT;
22 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
23 name 5-MeO-MIPT;
24 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
25 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
26 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
HB4352 - 43 - LRB103 35349 RLC 65413 b
HB4352- 44 -LRB103 35349 RLC 65413 b HB4352 - 44 - LRB103 35349 RLC 65413 b
HB4352 - 44 - LRB103 35349 RLC 65413 b
1 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
2 (4-HO-MiPT);
3 (82) Fluorophenylpiperazine;
4 (83) Methoxetamine;
5 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
6 ethcathinone).
7 (e) Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or
9 preparation which contains any quantity of the following
10 substances having a depressant effect on the central nervous
11 system, including its salts, isomers, and salts of isomers
12 whenever the existence of such salts, isomers, and salts of
13 isomers is possible within the specific chemical designation:
14 (1) mecloqualone;
15 (2) methaqualone; and
16 (3) gamma hydroxybutyric acid.
17 (f) Unless specifically excepted or unless listed in
18 another schedule, any material, compound, mixture, or
19 preparation which contains any quantity of the following
20 substances having a stimulant effect on the central nervous
21 system, including its salts, isomers, and salts of isomers:
22 (1) Fenethylline;
23 (2) N-ethylamphetamine;
24 (3) Aminorex (some other names:
25 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
26 4-5-dihydro-5-phenyl-2-oxazolamine) and its
HB4352 - 44 - LRB103 35349 RLC 65413 b
HB4352- 45 -LRB103 35349 RLC 65413 b HB4352 - 45 - LRB103 35349 RLC 65413 b
HB4352 - 45 - LRB103 35349 RLC 65413 b
1 salts, optical isomers, and salts of optical isomers;
2 (4) Methcathinone (some other names:
3 2-methylamino-1-phenylpropan-1-one;
4 Ephedrone; 2-(methylamino)-propiophenone;
5 alpha-(methylamino)propiophenone; N-methylcathinone;
6 methycathinone; Monomethylpropion; UR 1431) and its
7 salts, optical isomers, and salts of optical isomers;
8 (5) Cathinone (some trade or other names:
9 2-aminopropiophenone; alpha-aminopropiophenone;
10 2-amino-1-phenyl-propanone; norephedrone);
11 (6) N,N-dimethylamphetamine (also known as:
12 N,N-alpha-trimethyl-benzeneethanamine;
13 N,N-alpha-trimethylphenethylamine);
14 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
15 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
16 (8) 3,4-Methylenedioxypyrovalerone (MDPV);
17 (9) Halogenated amphetamines and
18 methamphetamines - any compound derived from either
19 amphetamine or methamphetamine through the substitution
20 of a halogen on the phenyl ring, including, but not
21 limited to, 2-fluoroamphetamine, 3-
22 fluoroamphetamine and 4-fluoroamphetamine;
23 (10) Aminopropylbenzofuran (APB):
24 including 4-(2-Aminopropyl) benzofuran, 5-
25 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
26 benzofuran, and 7-(2-Aminopropyl) benzofuran;
HB4352 - 45 - LRB103 35349 RLC 65413 b
HB4352- 46 -LRB103 35349 RLC 65413 b HB4352 - 46 - LRB103 35349 RLC 65413 b
HB4352 - 46 - LRB103 35349 RLC 65413 b
1 (11) Aminopropyldihydrobenzofuran (APDB):
2 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
3 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
4 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
5 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
6 (12) Methylaminopropylbenzofuran
7 (MAPB): including 4-(2-methylaminopropyl)
8 benzofuran, 5-(2-methylaminopropyl)benzofuran,
9 6-(2-methylaminopropyl)benzofuran
10 and 7-(2-methylaminopropyl)benzofuran.
11 (g) Temporary listing of substances subject to emergency
12 scheduling. Any material, compound, mixture, or preparation
13 that contains any quantity of the following substances:
14 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
15 (benzylfentanyl), its optical isomers, isomers, salts, and
16 salts of isomers;
17 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
18 phenylpropanamide (thenylfentanyl), its optical isomers,
19 salts, and salts of isomers.
20 (h) Synthetic cathinones. Unless specifically excepted,
21 any chemical compound which is not approved by the United
22 States Food and Drug Administration or, if approved, is not
23 dispensed or possessed in accordance with State or federal
24 law, not including bupropion, structurally derived from
25 2-aminopropan-1-one by substitution at the 1-position with
26 either phenyl, naphthyl, or thiophene ring systems, whether or
HB4352 - 46 - LRB103 35349 RLC 65413 b
HB4352- 47 -LRB103 35349 RLC 65413 b HB4352 - 47 - LRB103 35349 RLC 65413 b
HB4352 - 47 - LRB103 35349 RLC 65413 b
1 not the compound is further modified in one or more of the
2 following ways:
3 (1) by substitution in the ring system to any extent
4 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
5 halide substituents, whether or not further substituted in
6 the ring system by one or more other univalent
7 substituents. Examples of this class include, but are not
8 limited to, 3,4-Methylenedioxycathinone (bk-MDA);
9 (2) by substitution at the 3-position with an acyclic
10 alkyl substituent. Examples of this class include, but are
11 not limited to, 2-methylamino-1-phenylbutan-1-one
12 (buphedrone); or
13 (3) by substitution at the 2-amino nitrogen atom with
14 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
15 inclusion of the 2-amino nitrogen atom in a cyclic
16 structure. Examples of this class include, but are not
17 limited to, Dimethylcathinone, Ethcathinone, and
18 a-Pyrrolidinopropiophenone (a-PPP); or
19 Any other synthetic cathinone which is not approved by the
20 United States Food and Drug Administration or, if approved, is
21 not dispensed or possessed in accordance with State or federal
22 law.
23 (i) Synthetic cannabinoids or piperazines. Any synthetic
24 cannabinoid or piperazine which is not approved by the United
25 States Food and Drug Administration or, if approved, which is
26 not dispensed or possessed in accordance with State and
HB4352 - 47 - LRB103 35349 RLC 65413 b
HB4352- 48 -LRB103 35349 RLC 65413 b HB4352 - 48 - LRB103 35349 RLC 65413 b
HB4352 - 48 - LRB103 35349 RLC 65413 b
1 federal law.
2 (j) Unless specifically excepted or listed in another
3 schedule, any chemical compound which is not approved by the
4 United States Food and Drug Administration or, if approved, is
5 not dispensed or possessed in accordance with State or federal
6 law, and is derived from the following structural classes and
7 their salts:
8 (1) Benzodiazepine class: A fused 1,4-diazepine and
9 benzene ring structure with a phenyl connected to the
10 1,4-diazepine ring, with any substitution(s) or
11 replacement(s) on the 1,4-diazepine or benzene ring, any
12 substitution(s) on the phenyl ring, or any combination
13 thereof. Examples of this class include but are not
14 limited to: Clonazolam, Flualprazolam; or
15 (2) Thienodiazepine class: A fused 1,4-diazepine and
16 thiophene ring structure with a phenyl connected to the
17 1,4-diazepine ring, with any substitution(s) or
18 replacement(s) on the 1,4-diazepine or thiophene ring, any
19 substitution(s) on the phenyl ring, or any combination
20 thereof. Examples of this class include but are not
21 limited to: Etizolam.
22 (Source: P.A. 103-245, eff. 1-1-24.)
23 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
24 Sec. 206. (a) The controlled substances listed in this
25 Section are included in Schedule II.
HB4352 - 48 - LRB103 35349 RLC 65413 b
HB4352- 49 -LRB103 35349 RLC 65413 b HB4352 - 49 - LRB103 35349 RLC 65413 b
HB4352 - 49 - LRB103 35349 RLC 65413 b
1 (b) Unless specifically excepted or unless listed in
2 another schedule, any of the following substances whether
3 produced directly or indirectly by extraction from substances
4 of vegetable origin, or independently by means of chemical
5 synthesis, or by combination of extraction and chemical
6 synthesis:
7 (1) Opium and opiates, and any salt, compound,
8 derivative or preparation of opium or opiate, excluding
9 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
10 nalmefene, naloxone, and naltrexone, and their respective
11 salts, but including the following:
12 (i) Raw Opium;
13 (ii) Opium extracts;
14 (iii) Opium fluid extracts;
15 (iv) Powdered opium;
16 (v) Granulated opium;
17 (vi) Tincture of opium;
18 (vii) Codeine;
19 (viii) Ethylmorphine;
20 (ix) Etorphine Hydrochloride;
21 (x) Hydrocodone;
22 (xi) Hydromorphone;
23 (xii) Metopon;
24 (xiii) Morphine;
25 (xiii.5) 6-Monoacetylmorphine;
26 (xiv) Oxycodone;
HB4352 - 49 - LRB103 35349 RLC 65413 b
HB4352- 50 -LRB103 35349 RLC 65413 b HB4352 - 50 - LRB103 35349 RLC 65413 b
HB4352 - 50 - LRB103 35349 RLC 65413 b
1 (xv) Oxymorphone;
2 (xv.5) Tapentadol;
3 (xvi) Thebaine;
4 (xvii) Thebaine-derived butorphanol.
5 (xviii) Methorphan, except drug products
6 containing dextromethorphan that may be dispensed
7 pursuant to a prescription order of a practitioner and
8 are sold in compliance with the safety and labeling
9 standards as set forth by the United States Food and
10 Drug Administration, or drug products containing
11 dextromethorphan that are sold in solid, tablet,
12 liquid, capsule, powder, thin film, or gel form and
13 which are formulated, packaged, and sold in dosages
14 and concentrations for use as an over-the-counter drug
15 product. For the purposes of this Section,
16 "over-the-counter drug product" means a drug that is
17 available to consumers without a prescription and sold
18 in compliance with the safety and labeling standards
19 as set forth by the United States Food and Drug
20 Administration.
21 (2) Any salt, compound, isomer, derivative or
22 preparation thereof which is chemically equivalent or
23 identical with any of the substances referred to in
24 subparagraph (1), but not including the isoquinoline
25 alkaloids of opium;
26 (3) Opium poppy and poppy straw;
HB4352 - 50 - LRB103 35349 RLC 65413 b
HB4352- 51 -LRB103 35349 RLC 65413 b HB4352 - 51 - LRB103 35349 RLC 65413 b
HB4352 - 51 - LRB103 35349 RLC 65413 b
1 (4) Coca leaves and any salt, compound, isomer, salt
2 of an isomer, derivative, or preparation of coca leaves
3 including cocaine or ecgonine, and any salt, compound,
4 isomer, derivative, or preparation thereof which is
5 chemically equivalent or identical with any of these
6 substances, but not including decocainized coca leaves or
7 extractions of coca leaves which do not contain cocaine or
8 ecgonine (for the purpose of this paragraph, the term
9 "isomer" includes optical, positional and geometric
10 isomers);
11 (5) Concentrate of poppy straw (the crude extract of
12 poppy straw in either liquid, solid or powder form which
13 contains the phenanthrine alkaloids of the opium poppy).
14 (c) Unless specifically excepted or unless listed in
15 another schedule any of the following opiates, including their
16 isomers, esters, ethers, salts, and salts of isomers, whenever
17 the existence of these isomers, esters, ethers and salts is
18 possible within the specific chemical designation, dextrorphan
19 excepted:
20 (1) Alfentanil;
21 (1.1) Carfentanil;
22 (1.2) Thiafentanyl;
23 (2) Alphaprodine;
24 (3) Anileridine;
25 (4) Bezitramide;
26 (5) Bulk Dextropropoxyphene (non-dosage forms);
HB4352 - 51 - LRB103 35349 RLC 65413 b
HB4352- 52 -LRB103 35349 RLC 65413 b HB4352 - 52 - LRB103 35349 RLC 65413 b
HB4352 - 52 - LRB103 35349 RLC 65413 b
1 (6) Dihydrocodeine;
2 (7) Diphenoxylate;
3 (8) Fentanyl;
4 (9) Sufentanil;
5 (9.5) Remifentanil;
6 (10) Isomethadone;
7 (11) (Blank);
8 (12) Levorphanol (Levorphan);
9 (13) Metazocine;
10 (14) Methadone;
11 (15) Methadone-Intermediate,
12 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
13 (16) Moramide-Intermediate,
14 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
15 acid;
16 (17) Pethidine (meperidine);
17 (18) Pethidine-Intermediate-A,
18 4-cyano-1-methyl-4-phenylpiperidine;
19 (19) Pethidine-Intermediate-B,
20 ethyl-4-phenylpiperidine-4-carboxylate;
21 (20) Pethidine-Intermediate-C,
22 1-methyl-4-phenylpiperidine-4-carboxylic acid;
23 (21) Phenazocine;
24 (22) Piminodine;
25 (23) Racemethorphan;
26 (24) (Blank);
HB4352 - 52 - LRB103 35349 RLC 65413 b
HB4352- 53 -LRB103 35349 RLC 65413 b HB4352 - 53 - LRB103 35349 RLC 65413 b
HB4352 - 53 - LRB103 35349 RLC 65413 b
1 (25) Levo-alphacetylmethadol (some other names:
2 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
3 (d) Unless specifically excepted or unless listed in
4 another schedule, any material, compound, mixture, or
5 preparation which contains any quantity of the following
6 substances having a stimulant effect on the central nervous
7 system:
8 (1) Amphetamine, its salts, optical isomers, and salts
9 of its optical isomers;
10 (2) Methamphetamine, its salts, isomers, and salts of
11 its isomers;
12 (3) Phenmetrazine and its salts;
13 (4) Methylphenidate;
14 (5) Lisdexamfetamine.
15 (e) Unless specifically excepted or unless listed in
16 another schedule, any material, compound, mixture, or
17 preparation which contains any quantity of the following
18 substances having a depressant effect on the central nervous
19 system, including its salts, isomers, and salts of isomers
20 whenever the existence of such salts, isomers, and salts of
21 isomers is possible within the specific chemical designation:
22 (1) Amobarbital;
23 (2) Secobarbital;
24 (3) Pentobarbital;
25 (4) Pentazocine;
26 (5) Phencyclidine;
HB4352 - 53 - LRB103 35349 RLC 65413 b
HB4352- 54 -LRB103 35349 RLC 65413 b HB4352 - 54 - LRB103 35349 RLC 65413 b
HB4352 - 54 - LRB103 35349 RLC 65413 b
1 (6) Gluthethimide;
2 (7) (Blank).
3 (f) Unless specifically excepted or unless listed in
4 another schedule, any material, compound, mixture, or
5 preparation which contains any quantity of the following
6 substances:
7 (1) Immediate precursor to amphetamine and
8 methamphetamine:
9 (i) Phenylacetone
10 Some trade or other names: phenyl-2-propanone;
11 P2P; benzyl methyl ketone; methyl benzyl ketone.
12 (2) Immediate precursors to phencyclidine:
13 (i) 1-phenylcyclohexylamine;
14 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
15 (3) Nabilone.
16 (4) Xylazine: N-(2,6-dimethylpheny1)-5,6-dihydro-
17 4H-1,3-thiazin-2-amine), including its isomers, esters,
18 ethers, salts, and salts of isomers, esters, and ethers,
19 whenever the existence of such isomers, esters, ethers,
20 and salts is possible within the specific chemical
21 designation as a Schedule II controlled substance.
22 (g) Clonazolam.
23 (Source: P.A. 100-368, eff. 1-1-18.)
24 Section 95. No acceleration or delay. Where this Act makes
25 changes in a statute that is represented in this Act by text
HB4352 - 54 - LRB103 35349 RLC 65413 b
HB4352- 55 -LRB103 35349 RLC 65413 b HB4352 - 55 - LRB103 35349 RLC 65413 b
HB4352 - 55 - LRB103 35349 RLC 65413 b
HB4352 - 55 - LRB103 35349 RLC 65413 b